Effects of inhibitors of FGFR3 on gene transcription

US8158360B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Carla Heise · Benicia, US
• Esther Masih-Khan · Schreiber, CA
• Edward Moler · Aliso Viejo, US
• Michael Rowe · San Ramon, US
• Keith Stewart · Scottsdale, US
• Suzanne Trudel · Schreiber, CA

Key dates

• Filing date: Dec 7, 2006
• Grant date: Apr 17, 2012
• Expiry date: May 23, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/136
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 inhibition, are measured and identifications or adjustments may be made accordingly.